Autonomix Medical Inc (AMIX) Stock Analysis
Verdict: AVOID
Patent approval sparks speculative momentum, but zero revenue and a 6-month cash runway make imminent share dilution the central risk.
Investment score: 33/100
Analysis as of
Is Autonomix Medical Inc stock worth reviewing? AI model thesis
Autonomix Medical is a pre-revenue medical device microcap ($7.91M market cap) experiencing a temporary news-driven pop (+53.26% to $8.23) following patent grant news. However, with $7.00M in cash against $12.29M annual FCF burn, the company faces an urgent need for dilutive financing within ~6 months.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Autonomix Medical Inc opportunities and risks
What speaks for AMIX
- Patent Portfolio Expansion (U.S. Patent No. 12,714,780)
What speaks against AMIX
- Imminent Cash Exhaustion and High Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AMIX | n/a | 0.0x | n/a | 0.0% | 0.0% | -269.1% |
| HSCS | n/a | 1430.0x | 195.7x | -2982.1% | -211666.5% | -121.0% |
| SINT | n/a | 7.2x | n/a | -4.6% | -1303.4% | -103.6% |
| SCND | n/a | 1.7x | n/a | 29.2% | -13.0% | -69.0% |
| CODX | n/a | 1.9x | 0.0x | 8.1% | -6523.0% | -1976.7% |
| Peer median | n/a | 4.6x | n/a | 1.7% | -3913.2% | -112.3% |
Frequently asked questions about Autonomix Medical Inc (AMIX)
Is AMIX stock a good investment?
The cached TradeMates AI model rates Autonomix Medical Inc as AVOID with an investment score of 33/100. Autonomix Medical is a pre-revenue medical device microcap ($7.91M market cap) experiencing a temporary news-driven pop (+53.26% to $8.23) following patent grant news. However, with $7.00M in cash against $12.29M annual FCF burn, the company faces an urgent need for dilutive financing within ~6 months. This is algorithmic model output, not personal investment advice.
Is AMIX stock a buy?
The TradeMates model verdict for AMIX is AVOID with an investment score of 33/100. Treat this as a model signal to review, not a personal buy recommendation.